Search

Wei D Lu

from Newton Center, MA
Age ~54
Get Report
Also known as:
Wei H Lu, Wei Wei, Lu Wei
Phone and address:
554 Parker St, Newton, MA 02459
Related to:
Zhenshan Liu
Connected to:
Abigail I Lu, 32Aiping Lu, 54Allen C Lu, 46Anjian Lu, 84Anna G Lu, 67Anne B Lu, 72Arnold W Lu, 49Ava Lu, 36Ay K Lu, 54Barbara T Lu, 74

Wei Lu Phones & Addresses

  • 554 Parker St, Newton Center, MA 02459
  • Newton, MA
  • Chestnut Hill, MA
  • 34 Solar Cir, Parkville, MD 21234
  • 3 Barnwell Ct, Parkville, MD 21234
  • Baltimore, MD
  • Bowling Green, OH
  • Bethesda, MD

Work

Company: Ibm - Hopewell Junction, NY Oct 2000 Position: Development sciensist and engineer

Education

School / High School: University of Rhode Island- Kingston, RI May 1995 Specialities: PH.D. in Chemical Engineering

Ranks

Certificate: American Board of Internal Medicine Certification in Internal Medicine

Professional Records

Lawyers & Attorneys

Wei Lu Photo 1

Wei Lu - Lawyer

View page
Specialties:
International Trade
Commercial Law
Business Law
Immigration Law
ISLN:
911506073
Admitted:
1983
University:
Oregon State University, B.S., 1968; Oregon State University, M.B.A., 1972
Law School:
Western State University, J.D., 1982
Wei Lu Photo 2

Wei Lu - Lawyer

View page
Specialties:
Intellectual Property Law
ISLN:
922651428
Admitted:
2014
University:
Santa Clara Univ SOL, Santa Clara, CA; Univ of Texas, Austin, TX
Law School:
Santa Clara University School of Law, JD - Juris Doctor, 2013

Medicine Doctors

Wei Lu Photo 3

Dr. Wei X Lu - MD (Doctor of Medicine)

View page
Hospitals:
827 Linden Ave, Baltimore, MD 21201

Maryland General Hospital
827 Linden Avenue, Baltimore, MD 21201

MedStar Union Memorial Hospital
201 East University Parkway, Baltimore, MD 21218

Mercy Medical Center
345 Saint Paul Place, Baltimore, MD 21202

Mercy Medical Center
301 Saint Paul St, Baltimore, MD 21202

Union Memorial Hospital
3333 N Calvert St, Baltimore, MD 21218

Maryland General Hospital
827 Linden Ave, Baltimore, MD 21201
Education:
Medical Schools
Shanghai School Of Medicine
Graduated: 1991
Wei Lu Photo 4

Wei X. Lu

View page
Specialties:
Nephrology, Internal Medicine
Work:
Metro Renal AssociatesMetro Renal Associates LLC
821 N Eutaw St STE 407, Baltimore, MD 21201
(410) 439-1332 (phone), (410) 439-1335 (fax)

DaVita Downtown Dialysis Center
821 N Eutaw St STE 401, Baltimore, MD 21201
(410) 383-3450 (phone), (410) 383-3468 (fax)
Education:
Medical School
Shanghai Med Univ, Shanghai First Med Univ, Shanghai, China
Graduated: 1991
Procedures:
Dialysis Procedures
Conditions:
Chronic Renal Disease
Disorders of Lipoid Metabolism
Hypertension (HTN)
Languages:
English
Description:
Dr. Lu graduated from the Shanghai Med Univ, Shanghai First Med Univ, Shanghai, China in 1991. She works in Baltimore, MD and 1 other location and specializes in Nephrology and Internal Medicine. Dr. Lu is affiliated with Medstar Union Memorial Hospital, Mercy Medical Center and University Of Maryland Medical Center.
Wei Lu Photo 5

Dr. Wei Lu - MD (Doctor of Medicine)

View page
Hospitals:
827 Linden Ave, Baltimore, MD 21201

Maryland General Hospital
827 Linden Avenue, Baltimore, MD 21201

MedStar Union Memorial Hospital
201 East University Parkway, Baltimore, MD 21218

Mercy Medical Center
345 Saint Paul Place, Baltimore, MD 21202
Education:
Medical Schools
University Of Maryland At Baltimore / Professional Schools
Wei Lu Photo 6

Wei Lu, Greenbelt MD

Work:
Sidhu Singh & Pollak
7525 Greenway Center Dr, Greenbelt, MD 20770
Metro Renal Assoc
3333 N Calvert St, Baltimore, MD 21218
Wei Lu Photo 7

Wei X Lu, Baltimore MD

View page
Specialties:
Nephrologist
Address:
821 N Eutaw St, Baltimore, MD 21201
Education:
University of Maryland (Baltimore) - Doctor of Philosophy
Shanghai Medical University - Doctor of Medicine
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine
American Board of Internal Medicine Sub-certificate in Nephrology (Internal Medicine)

Resumes

Resumes

Wei Lu Photo 8

Wei Lu Poughkeepsie, NY

View page
Work:
IBM
Hopewell Junction, NY
Oct 2000 to Dec 2013
Development Sciensist and Engineer
Micrion Corporation
Peabody, MA
May 1996 to Sep 2000
Applications Engineer
Environmental Science Services (ESS)
Providence, RI
Sep 1994 to Feb 1996
Senior Engineer
University of Rhode Island
Kingston, RI
1990 to 1994
Research Assistant
Heat Transfer Process Design and Consulting

1985 to 1988
R&D Engineer
Heat Transfer Process Design and Consulting

1985 to 1988
Manager
Education:
University of Rhode Island
Kingston, RI
May 1995
PH.D. in Chemical Engineering
Tianjin University
May 1985
M.S. in Chemical Engineering
Tianjin University
Jul 1982
B. S. in Polymer Science

Business Records

Name / Title
Company / Classification
Phones & Addresses
Wei Lu
Partner
Canaan Homes, LLC
Single-Family House Construction
10500 Billy Lilly Ct, Laurel, MD 20723
Wei Lu
Vice president
SIYUAN ASSOCIATION FOR INNOVATION & SUSTAINABILITY
61 Wayne Rd, Needham Heights, MA 02494
61 Wayne Rd Needham Ma 02494 Usa<Br/>61 Wayne Rd Needham, Needham Heights, MA 02494
Wei Lu
Managing
Cheng Du LLC
Wei X. Lu
Nephrology
Metro Renal
Hospital & Health Care · Medical Doctor's Office · Internist
821 N Eutaw St, Baltimore, MD 21201
(410) 225-8947
Wei Xue Lu
Wei Lu MD,PHD
Internist
3333 N Calvert St, Baltimore, MD 21218
(410) 261-8558

Publications

Us Patents

Nanostructures Containing Metal Semiconductor Compounds

View page
US Patent:
20090004852, Jan 1, 2009
Filed:
Dec 9, 2005
Appl. No.:
10/588833
Inventors:
Charles M. Lieber - Lexington MA, US
Yue Wu - Cambridge MA, US
Jie Xiang - Cambridge MA, US
Chen Yang - Somerville MA, US
Wei Lu - Ann Arbor MI, US
Assignee:
President and Fellows of Havard College - Cambridge MA
International Classification:
H01L 21/44
US Classification:
438664, 257E21199
Abstract:
A network element (), such as a Packet Data Serving Node, detects () a change in operational status of a mobile station during a communication session and, in response to detecting such a change, automatically increases () memory capacity as is available to support additional communication sessions while simultaneously persisting at least some session information for potential subsequent use during the communication session. For example, this response can occur upon detecting that a mobile station has changed from an active to a dormant status. Then, upon returning to an active status, the network element can use the persisted information to facilitate rapid reconstruction of infrastructure support for the mobile station's call participation.

Nanoscale Wire-Based Memory Devices

View page
US Patent:
20110001117, Jan 6, 2011
Filed:
Jan 21, 2009
Appl. No.:
12/746791
Inventors:
Charles M. Lieber - Lexington MA, US
Yajie Dong - Cambridge MA, US
Wei Lu - Ann Arbor MI, US
Guihua Yu - Cambridge MA, US
Assignee:
President and Fellows of Harvard College - Cambridge MA
International Classification:
H01L 29/66
H01L 21/60
US Classification:
257 9, 438468, 977762, 257E29168, 257E21506
Abstract:
The present invention generally relates to nanotechnology and sub-microelectronic devices that can be used in circuitry, and, in particular, to nanoscale wires and other nanostructures able to encode data. One aspect of the present invention is directed to a device comprising an electrical crossbar array comprising at least two crossed wires at a cross point. In some cases, at least one of the crossed wires is a nanoscale wire, and in certain instances, at least one of the crossed wires is a nanoscale wire comprising a core and at least one shell surrounding the core. For instance, the core may comprise a crystal (e.g., crystalline silicon) and the shell may be at least partially amorphous (e.g., amorphous silicon). In certain embodiments, the cross point may exhibit intrinsic current rectification, or other electrical behaviors, and the cross point can be used as a memory device. For example, in one embodiment, the cross point may exhibit a first conductance at a positive voltage, and the cross point may exhibit a second conductance at a negative voltage. Accordingly, by applying suitable voltages to the cross point, data may be stored at the cross point. Other aspects of the present invention are directed to systems and methods for making or using such devices, kits involving such devices, or the like.

Pyridin-2(1H)-One Quinolinone Derivatives As Mutant-Isocitrate Dehydrogenase Inhibitors

View page
US Patent:
20230125739, Apr 27, 2023
Filed:
Nov 9, 2022
Appl. No.:
17/984069
Inventors:
- Watertown MA, US
Anna Ericsson - Shrewsbury MA, US
Ann-Marie Campbell - Monroe CT, US
Gary Gustafson - Ridgefield CT, US
Zhongguo Wang - Lexington MA, US
R. Bruce Diebold - Waltham MA, US
Susan Ashwell - Carlisle MA, US
Justin Andrew Caravella - Cambridge MA, US
Wei Lu - Newton MA, US
Assignee:
FORMA Therapeutics, Inc. - Watertown MA
International Classification:
C07D 401/12
C07D 401/14
C07D 471/04
A61P 35/00
Abstract:
The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula:where A, U, W, W, W, R-R, and Rare described herein.

Treating Patients Harboring An Isocitrate Dehydrogenase-1 (Idh-1) Mutation

View page
US Patent:
20230101121, Mar 30, 2023
Filed:
Nov 14, 2022
Appl. No.:
17/986414
Inventors:
- Watertown MA, US
Alan Collis - Lexington MA, US
Jeff Davis - Hingham MA, US
Duncan Walker - Boulder CO, US
Susan Ashwell - Carlisle MA, US
Blythe Thomson - Cincinnati OH, US
Wei Lu - Newton MA, US
Assignee:
FORMA Therapeutics, Inc. - Watertown MA
International Classification:
A61K 31/4709
A61P 35/02
C12Q 1/686
C12Q 1/6886
Abstract:
Methods of treating patients diagnosed with AML or MDS harboring mutant IDH-1 include detecting an IDH1 mutation and the therapeutic administration of an inhibitor of a mutant IDH-1 as a single agent, or in combination with azacitidine (AZA) or cytarabine.

Inhibiting Mutant Isocitrate Dehydrogenase 1 (Midh-1)

View page
US Patent:
20230066088, Mar 2, 2023
Filed:
Mar 21, 2022
Appl. No.:
17/700027
Inventors:
- Watertown MA, US
Susan Ashwell - Carlisle MA, US
Blythe Thomson - Cincinnati OH, US
Alan Collis - Lexington MA, US
Jeff Davis - Hingham MA, US
Duncan Walker - Boulder CO, US
Wei Lu - Newton MA, US
International Classification:
A61K 31/4709
A61P 35/00
Abstract:
Patients diagnosed with a cancer harboring an IDH-1 mutation can be treated by the administration of a therapeutically effective amount of a pharmaceutical composition comprising Compound 1, a selective inhibitor of 2-HG production from mIDH-1 enzymes including the R132 mutations R132C, R132H, R132L, R132G, and R132S.

Inhibiting Mutant Isocitrate Dehydrogenase 1 (Midh-1)

View page
US Patent:
20210244727, Aug 12, 2021
Filed:
Apr 28, 2021
Appl. No.:
17/243177
Inventors:
- Watertown MA, US
Blythe THOMSON - Cincinnati OH, US
Patrick F. KELLY - Concord MA, US
Alan COLLIS - Lexington MA, US
Jeff DAVIS - Hingham MA, US
Duncan WALKER - Boulder CO, US
Wei LU - Newton MA, US
International Classification:
A61K 31/4709
A61K 31/706
A61P 35/00
A61P 35/02
Abstract:
Patients diagnosed with a cancer harboring an IDH-1 mutation can be treated by the administration of a therapeutically effective amount of a pharmaceutical composition comprising Compound 1, a selective inhibitor of 2-HG production from mIDH-1 enzymes including the R132 mutations R132C, R132H, R132L, R132G, and R132S.

Novel Compounds And Compositions For Inhibition Of Fasn

View page
US Patent:
20210214323, Jul 15, 2021
Filed:
Feb 26, 2021
Appl. No.:
17/187061
Inventors:
- Watertown MA, US
Hongbin LI - Watertown MA, US
James Loch - Watertown MA, US
Wei Lu - Newton MA, US
Matthew W. Martin - Arlington MA, US
David S. Millan - Watertown MA, US
Shawn E.R. Schiller - Watertown MA, US
Mark J. Tebbe - Arlington MA, US
International Classification:
C07D 295/192
A61K 45/06
C07D 215/14
C07D 231/56
C07D 405/12
C07D 413/12
C07D 417/12
C07D 471/04
C07D 257/04
C07D 487/04
C07D 263/57
C07D 491/048
C07D 271/12
C07D 495/04
C07D 209/18
C07D 277/62
C07D 277/66
C07D 513/04
C07D 213/56
C07D 305/08
A61K 31/4965
A61P 35/00
A61K 31/495
A61K 31/496
A61K 31/497
A61K 31/4985
A61K 31/5025
A61K 31/506
C07D 209/08
C07D 213/65
C07D 213/69
C07D 217/16
C07D 231/12
C07D 235/08
C07D 401/04
C07D 403/04
C07D 417/04
Abstract:
The present invention relates to compounds and composition for inhibition of FASN, their synthesis, applications, and antidotes. An illustrative compound of the invention is shown below:

Treating Patients Harboring An Isocitrate Dehydrogenase 1 (Idh-1) Mutation

View page
US Patent:
20210085669, Mar 25, 2021
Filed:
Dec 4, 2020
Appl. No.:
17/112269
Inventors:
- Watertown MA, US
Alan Collis - Lexington MA, US
Jeff Davis - Hingham MA, US
Duncan Walker - Boulder CO, US
Susan Ashwell - Carlisle MA, US
Blythe Thomson - Cincinnati OH, US
Wei Lu - Newton MA, US
International Classification:
A61K 31/4709
A61P 35/02
C12Q 1/686
C12Q 1/6886
Abstract:
Methods of treating patients diagnosed with AML or MDS harboring mutant IDH-1 include detecting an IDH1 mutation and the therapeutic administration of an inhibitor of a mutant IDH-1 as a single agent, or in combination with azacitidine (AZA) or cytarabine.

Isbn (Books And Publications)

Cell Activation And Apoptosis in HIV Infection: Implications for Pathogenesis and Therapy

View page
Author

Wei Lu

ISBN #

0306450631

ICO20: Materials and Nanostructures 21-26 August, 2005, Changchun, China

View page
Author

Wei Lu

ISBN #

0819460605

Control profile
Wei D Lu from Newton Center, MA, age ~54 Get Report